News | February 28, 2025
Sanofi India declares 8% growth in net sales for Q4-2024
Standalone profit from operations for Q4-2024 were Rs. 108 crore
Standalone profit from operations for Q4-2024 were Rs. 108 crore
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain
Among those identified, 2.4 lakh patients have been notified from public health institutions, while 1.1 lakh were identified through private healthcare facilities
The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
Collaborates with VisionSpring to conduct eye check-up camps for underprivileged children
Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market
IMCD India’s innovative formulations bring the Skinification trend to life with cutting-edge solutions across beauty and personal care
Next-generation lens features purely refractive design, delivering uninterrupted high-quality vision with high best-in-category contrast & low-light performance
Subscribe To Our Newsletter & Stay Updated
